Literature DB >> 22763136

Modeling the inhibition of breast cancer growth by GM-CSF.

Barbara Szomolay1, Tim D Eubank, Ryan D Roberts, Clay B Marsh, Avner Friedman.   

Abstract

M-CSF is overexpressed in breast cancer and is known to stimulate macrophages to produce VEGF resulting in angiogenesis. It has recently been shown that the growth factor GM-CSF injected into murine breast tumors slowed tumor growth by secreting soluble VEGF receptor-1 (sVEGFR-1) that binds and inactivates VEGF. This study presents a mathematical model that includes all the components above, as well as MCP-1, tumor cells, and oxygen. The model simulations are representative of the in vivo data through predictions of tumor growth using different protocol strategies for GM-CSF for the purpose of predicting higher degrees of treatment success. For example, our model predicts that once a week dosing of GM-CSF would be less effective than daily, twice a week, or three times a week treatment because of the presence of essential factors required for the anti-tumor effect of GM-CSF.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763136      PMCID: PMC6860914          DOI: 10.1016/j.jtbi.2012.03.024

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  56 in total

1.  The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.

Authors:  Sławomir Ławicki; Maciej Szmitkowski; Marek Wojtukiewicz
Journal:  Clin Chim Acta       Date:  2006-04-21       Impact factor: 3.786

2.  GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

Authors:  Tim D Eubank; Ryan Roberts; Michelle Galloway; Yijie Wang; David E Cohn; Clay B Marsh
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

3.  Association between serum macrophage colony-stimulating factor levels and monocyte and thrombocyte counts in healthy, hypoxic, and septic term neonates.

Authors:  H Oren; N Duman; H Abacioglu; H Ozkan; G Irken
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

4.  Openings between defective endothelial cells explain tumor vessel leakiness.

Authors:  H Hashizume; P Baluk; S Morikawa; J W McLean; G Thurston; S Roberge; R K Jain; D M McDonald
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

5.  M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes?

Authors:  R Tang; F Beuvon; M Ojeda; V Mosseri; P Pouillart; S Scholl
Journal:  J Cell Biochem       Date:  1992-12       Impact factor: 4.429

Review 6.  Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes.

Authors:  E J Leonard; A Skeel; T Yoshimura; J Rankin
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

7.  Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression.

Authors:  Hiroshi Fujimoto; Takafumi Sangai; Genichiro Ishii; Akashi Ikehara; Takeshi Nagashima; Masaru Miyazaki; Atsushi Ochiai
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

8.  Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma.

Authors:  Annamaria Rapella; Anna Negrioli; Giovanni Melillo; Sandra Pastorino; Luigi Varesio; Maria Carla Bosco
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

Review 9.  Macrophages: modulators of breast cancer progression.

Authors:  Elaine Y Lin; Jeffrey W Pollard
Journal:  Novartis Found Symp       Date:  2004

10.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  11 in total

1.  Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.

Authors:  Xiulan Lai; Andrew Stiff; Megan Duggan; Robert Wesolowski; William E Carson; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

2.  Transmissible ER stress between macrophages and tumor cells configures tumor microenvironment.

Authors:  Wei Wei; Yazhuo Zhang; Qiaoling Song; Qianyue Zhang; Xiaonan Zhang; Xinning Liu; Zhihua Wu; Xiaohan Xu; Yuting Xu; Yu Yan; Chenyang Zhao; Jinbo Yang
Journal:  Cell Mol Life Sci       Date:  2022-07-07       Impact factor: 9.207

3.  Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: a mathematical model.

Authors:  Duan Chen; Julie M Roda; Clay B Marsh; Timothy D Eubank; Avner Friedman
Journal:  Bull Math Biol       Date:  2012-10-17       Impact factor: 1.758

4.  Mathematical modeling of interleukin-27 induction of anti-tumor T cells response.

Authors:  Kang-Ling Liao; Xue-Feng Bai; Avner Friedman
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

5.  Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Authors:  Kang-Ling Liao; Xue-Feng Bai; Avner Friedman
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

6.  Exosomal miRs in Lung Cancer: A Mathematical Model.

Authors:  Xiulan Lai; Avner Friedman
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

7.  How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?

Authors:  Xiulan Lai; Avner Friedman
Journal:  BMC Syst Biol       Date:  2019-03-13

8.  Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells.

Authors:  Jesse D Plotkin; Michael G Elias; Mohammad Fereydouni; Tracy R Daniels-Wells; Anthony L Dellinger; Manuel L Penichet; Christopher L Kepley
Journal:  Front Immunol       Date:  2019-02-18       Impact factor: 7.561

9.  CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis.

Authors:  Surendra K Shukla; Chunbo He; Ryan J King; Enza Vernucci; Ravi Thakur; Kuldeep S Attri; Aneesha Dasgupta; Nina V Chaika; Scott E Mulder; Jaime Abrego; Divya Murthy; Venugopal Gunda; Camila G Pacheco; Paul M Grandgenett; Audrey J Lazenby; Michael A Hollingsworth; Fang Yu; Kamiya Mehla; Pankaj K Singh
Journal:  Oncogene       Date:  2022-01-10       Impact factor: 8.756

10.  Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.

Authors:  Wenrui Hao; Avner Friedman
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.